

# Conversion of GalNAc $\beta$ (1–4)GlcNAc $\beta$ -OMe into GalNAc $\beta$ (1–4)-[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe using human milk $\alpha$ 3/4-fucosyltransferase

## Synthesis of a novel terminal element in glycoprotein glycans

Aldert A. Bergwerff<sup>a</sup>, J. Albert van Kuik<sup>a</sup>, Wietske E.C.M. Schiphorst<sup>b</sup>, Carolien A.M. Koeleman<sup>b</sup>, Dirk H. van den Eijnden<sup>b</sup>, Johannes P. Kamerling<sup>a,\*</sup>, Johannes F.G. Vliegthart<sup>a</sup>

<sup>a</sup>*Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University, PO Box 80075, 3508 TB Utrecht, The Netherlands*

<sup>b</sup>*Department of Medical Chemistry, Vrije Universiteit, Amsterdam, The Netherlands*

Received 31 August 1993; revised version received 15 September 1993

Incubation of GalNAc $\beta$ (1–4)GlcNAc $\beta$ -OMe with GDP-Fuc in the presence of human milk  $\alpha$ 3/4-fucosyltransferase resulted in the formation of GalNAc $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe. Under conditions that led to complete  $\alpha$ 3-fucosylation of Gal $\beta$ (1–4)GlcNAc $\beta$ -OEt, GalNAc $\beta$ (1–4)GlcNAc $\beta$ -OMe was fucosylated for more than 85%. For the identification of the isolated fucosylated products one- and two-dimensional <sup>1</sup>H-NMR spectroscopy was applied. In vacuo molecular dynamics simulations of Gal $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OEt and GalNAc $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe using the CHARMM based force field CHEAT, demonstrated only small differences between the conformations of these compounds. This illustrates the minor conformational influence of the substituent at C-2', i.e. a hydroxyl function versus a *N*-acetyl group.

<sup>1</sup>Fucosyltransferase; GalNAc-containing N-glycan; Conformational analysis; Lewis x

## 1. INTRODUCTION

A structural variant of the Le<sup>x</sup> oligosaccharide element Gal $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ , namely GalNAc $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ , has been demonstrated to occur in O-linked oligosaccharides of the sea squirt H-antigen [1]. Recently, this structural variant was also identified as a terminal element in N-linked carbohydrate chains derived from human urinary-type plasminogen activator [2], from *Schistosoma mansoni* glycoproteins [3], from honeybee venom phospholipase A<sub>2</sub> [4] and from bovine pro-opiomelanocortin [5].

The biosynthesis of the Le<sup>x</sup> determinant is known to proceed by the ordered addition of  $\beta$ Gal in (1–4)-linkage and  $\alpha$ Fuc in (1–3)-linkage to a terminal GlcNAc residue (for a review see [6]). Human milk has been demonstrated to contain at least two different  $\alpha$ 3/4-fucosyltransferase activities, which both are capable of catalyzing the synthesis of the Le<sup>x</sup> sequence [6]. Human

milk  $\alpha$ 3/4-fucosyltransferase preparations have been used in the synthesis of the Le<sup>y</sup> epitope [7], the  $\alpha$ (2–3)-sialylated Le<sup>x</sup> determinant (SLe<sup>x</sup>) [8], the  $\alpha$ (1–3)-galactosylated Le<sup>x</sup> tetrasaccharide [9], and the 3'-*O*-sulfated Le<sup>x</sup> trisaccharide (T. De Vries and D.H. Van den Eijnden, unpublished results), indicating that substitution at C-2 or C-3 of the Gal moiety in the Gal $\beta$ (1–4)GlcNAc $\beta$  acceptor substrate does not impair the transfer of Fuc to C-3 of the GlcNAc residue. In view of this acceptor property it was of interest to investigate whether the human milk preparation could also function in the synthesis of the GalNAc variant of Le<sup>x</sup>.

## 2. MATERIALS AND METHODS

### 2.1. Materials

GalNAc $\beta$ (1–4)GlcNAc $\beta$ -OMe (GNGn) was a generous gift of Dr. J.G.M. Van der Ven [10]. Gal $\beta$ (1–4)GlcNAc $\beta$ -OEt (GGn) and GDP-Fuc were obtained from BioCarb AB, Lund, Sweden. GDP-[<sup>3</sup>H]Fuc (7 Ci/mmol) was purchased from DuPont NEN (Boston, MA), and was diluted with unlabelled GDP-Fuc. Partially purified human milk  $\alpha$ 3/4-fucosyltransferase, kindly provided by Mrs. T. De Vries, was isolated from pooled human milk as described in [11] with minor modifications [12]. The resulting preparation contained the enzyme in a 225-fold purified form (1.4 mU/ml) in a solution of 50 mM sodium cacodylate buffer, pH 7.2, containing 50% (by vol.) glycerol, 100 mM NaCl, 5 mM MgCl<sub>2</sub> and 0.05% sodium azide.

### 2.2. Enzymic conversions and isolation of the products

The incubation mixtures used for fucosylation of GNGn and GGn contained in a volume of 1 ml: 1  $\mu$ mol acceptor oligosaccharide, 1.5  $\mu$ mol GDP-[<sup>3</sup>H]Fuc (0.5 Ci/mol), 50  $\mu$ mol 3-(*N*-morpholino)-

\*Corresponding author. Fax: (31) (30) 540 980.

**Abbreviations:** Fuc, fucose; Neu5Ac, *N*-acetylneuraminic acid; Le<sup>x</sup>, Lewis x; 1D, one dimensional; 2D, two-dimensional; COSY, correlation spectroscopy; HOHAHA, homonuclear Hartmann–Hahn; MLEV, composite pulse devised by Malcom Levitt; r.O.e., rotating frame nuclear Overhauser enhancement; ROESY, rotating frame nuclear Overhauser enhancement spectroscopy; CHEAT, carbohydrate hydroxyls represented by extended atoms; CHARMM, Molecular Simulations Inc. version of Chemistry Harvard macromolecular mechanics; MD, molecular dynamics.

propanesulfonate (MOPS/NaOH) buffer pH 7.5, 4  $\mu$ mol ATP, 10  $\mu$ mol  $\text{MnCl}_2$ , and 1.4 mU of the  $\alpha$ 3/4-fucosyltransferase preparation mentioned above. The mixtures were incubated for 44 h at 37°C, and passed over a column (2.5 ml) of Dowex 1-X8 ( $\text{Cl}^-$  form). In each case, the columns were washed with 3 bed volumes of  $\text{H}_2\text{O}$ , and the combined eluate and washes were lyophilized. Then, the samples were fractionated on a column (1.6  $\times$  200 cm) of Bio-Gel P-4 (200 400 mesh, Bio-Rad) equilibrated in and eluted with 0.05 M ammonium acetate buffer, pH 5.2, at a flow rate of 17 ml/min and 27°C. Fractions of 4 ml were collected and small aliquots were assayed for  $^3\text{H}$ -radioactivity by liquid scintillation counting. Radioactive fractions were further analyzed by high-pH anion-exchange chromatography (HPAEC) in a system consisting of a Dionex Bio-LC gradient pump, a CarboPac MA-1 column (4.0  $\times$  250 mm) and a Model PAD 2 detector. The pulse potentials and durations used for the pulsed- amperometric detection (PAD) were  $E_1 = 0.05$  V ( $t_1 = 480$  ms);  $E_2 = 0.60$  V ( $t_2 = 120$  ms);  $E_3 = -0.60$  V ( $t_3 = 60$  ms); response time 1 s. Isocratic elution was performed using 0.1 M NaOH at a flow rate of 0.4 ml/min. Bio-Gel P-4 fractions that appeared to contain  $^3\text{H}$ -labelled carbohydrate material and no unconverted substrate were pooled, lyophilized and desalted on a column (1.0  $\times$  45 cm) of Bio-Gel P-2 (200–400 mesh), eluted with  $\text{H}_2\text{O}$ .

### 2.3. Molecular dynamics simulations

Molecular dynamics simulations were performed using CHEAT, a CHARMM based force field for carbohydrates [13], in which carbohydrate hydroxyl groups are represented by extended atoms to prevent the formation of intramolecular hydrogen bonds. This force field was adapted (Dr. L.M.J. Kroon-Batenburg, Department of Crystal and Structural Chemistry, Utrecht University, unpublished data) to be used with the molecular modelling package INSIGHT/DISCOVER (Biosym Technologies Inc.). The two fucosylated carbohydrate structures were created graphically with the initial interglycosidic torsion angles conform those of the minimum energy conformations of the  $\text{Le}^x$  trisaccharide [14]. The atoms of the methyl, ethyl and *N*-acetyl substituents were implemented in these models on basis of the existing general valence force field (CHARMM). After initial energy minimisation, the in vacuo dynamics simulations were run for 1 ns, with a time step of 0.001 ps at a constant temperature of 27°C. The first 100 ps of each run were considered to be the equilibration time, then data were stored every 1 ps. The calculations were performed on a Silicon Graphics Iris Indigo R3000. The interglycosidic torsion angles  $\Phi$  and  $\Psi$  are defined as  $\text{O}_5\text{--C}_1\text{--O}_x\text{--C}_x$  and  $\text{C}_1\text{--O}_x\text{--C}_x\text{--C}_{x+1}$ , respectively, where  $\text{O}_x$ ,  $\text{C}_x$  and  $\text{C}_{x+1}$  are aglyconic atoms (IUPAC convention [15]).

### 2.4. $^1\text{H}$ -NMR spectroscopy

1D 500- and 600-MHz  $^1\text{H}$ -NMR spectra were recorded as described [16,17]. In the case of 2D NMR experiments, data matrices of  $512 \times 2048$  points were recorded at temperatures as indicated in section 3, using Bruker NMR-software and the time-proportional phase increment method. The  $^1\text{HO}^2\text{H}$  signal was presaturated for 1 s during the relaxation delay. 500-MHz 2D HOHAHA spectra of **GNGn** and  $\text{GalNAc}\beta(1\text{--}4)[\text{Fuc}\alpha(1\text{--}3)]\text{GlcNAc}\beta\text{-OMe}$  (**GN(F)Gn**) were recorded using a MLEV-17 mixing sequence of 120 ms, and a spin-lock field-strength corresponding to a  $90^\circ$   $^1\text{H}$  pulse-width of 28.1  $\mu\text{s}$ . For **GNGn** the data matrix represented in each dimension a spectral width of 3106 Hz, and for **GN(F)Gn** of 3817 Hz. The 2D HOHAHA spectrum of  $\text{Gal}\beta(1\text{--}4)[\text{Fuc}\alpha(1\text{--}3)]\text{GlcNAc}\beta\text{-OEt}$  (**G(F)Gn**) was recorded at 600 MHz, using a MLEV-17 mixing sequence of 120 ms, a spin-lock field-strength corresponding to a  $90^\circ$   $^1\text{H}$  pulse-width of 28.2  $\mu\text{s}$ , and a data matrix representing a spectral width of 4505 Hz in each dimension. The 500-MHz 2D ROESY spectra of **GNGn** and **GN(F)Gn** were acquired, using a spin-lock mixing pulse of 200 ms at a field-strength corresponding to a  $90^\circ$   $^1\text{H}$  pulse-width of 112.3  $\mu\text{s}$ . The data matrices represented a spectral width of 3106 Hz and 4274 Hz in each dimension for **GNGn** and **GN(F)Gn**, respectively. In the case of **GNGn**, the carrier-frequency was placed on the  $^1\text{HO}^2\text{H}$ -line at 4.94 ppm, whereas for **GN(F)Gn** it was placed 200 Hz upfield from the Fuc H-1 signal. The 500-MHz double quantum filtered  $^1\text{H}$ - $^1\text{H}$  2D COSY spectra of

**GNGn** and **GN(F)Gn** were obtained with a spectral width of 3106 Hz for **GNGn**, and 3816 Hz for **GN(F)Gn**, respectively, in each dimension. The 600-MHz double quantum filtered  $^1\text{H}$ - $^{11}\text{H}$  2D COSY spectrum of **G(F)Gn** was acquired with a spectral width of 4506 Hz in each dimension. The time domain data of the COSY, HOHAHA and ROESY experiments, were zero-filled to  $1024 \times 2048$  data matrices prior to multiplication with a squared-bell function, phase shifted by  $\pi/3$ .

## 3. RESULTS

Incubation of  $\text{GalNAc}\beta(1\text{--}4)\text{GlcNAc}\beta\text{-OMe}$  (**GNGn**) with GDP-Fuc in the presence of human milk  $\alpha$ 3/4-fucosyltransferase afforded  $\text{GalNAc}\beta(1\text{--}4)[\text{Fuc}\alpha(1\text{--}3)]\text{GlcNAc}\beta\text{-OMe}$  (**GN(F)Gn**). In a similar way, incubation of  $\text{Gal}\beta(1\text{--}4)\text{GlcNAc}\beta\text{-OEt}$  (**GFn**) yielded the  $\text{Le}^x$  trisaccharide  $\text{Gal}\beta(1\text{--}4)[\text{Fuc}\alpha(1\text{--}3)]\text{GlcNAc}\beta\text{-OEt}$  (**GN(F)Gn**). Under the conditions that resulted in complete conversion of **GFn**, more than 85% of **GNGn** was transformed. Isolation of the products was achieved by Bio-Gel P-4 filtration (Fig. 1), using HPAEC-PAD as a monitoring system to allow the identification of fractions containing only product (**G(F)Gn**, retention time ( $t_r$ ) 4.8 min; **GN(F)Gn**,  $t_r$  5.0 min) and no starting material (**GFn**,  $t_r$  5.3 min; **GNGn**,  $t_r$  7.7 min).

Complete unravelling of the 1D  $^1\text{H}$ -NMR spectra of **GN(F)Gn** (Fig. 2) and **GNGn** was carried out by apply-




Fig. 1. Isolation of the products of  $\alpha$ 3-fucosylation catalyzed by the human milk enzyme of **G(F)Gn** (upper panel) and **GN(F)Gn** (lower panel) by Bio-Gel P-4 chromatography. Of the radioactive fractions number 75–78 (upper panel) and 71–72 (lower panel), respectively, were pooled, lyophilized and the materials were analyzed by  $^1\text{H}$ -NMR spectroscopy. The radioactive materials eluting in fractions 85–88 and 92–98 are degradation products of GDP- $^3\text{H}$ Fuc.




Fig. 2. Resolution-enhanced 500-MHz  $^1\text{H}$ -NMR spectrum at 300 K of  $\text{GalNAc}\beta(1-4)[\text{Fuc}\alpha(1-3)]\text{GlcNAc}\beta\text{-OMe}$ . The letters and numbers refer to the residues in the structure and to the protons in that residue.

ing 2D COSY, HOHAHA and ROESY experiments. In order to obtain an increased intensity for the r.O.e. cross-peaks, the 2D ROESY spectra were measured at 285 K. COSY and HOHAHA spectra were measured at 285 K to attain identical chemical shifts for the corresponding protons in each 2D spectrum, and at 300 K for comparison with standard structural-reporter-group data. The spectral data are listed in Table I. For both compounds the assignment of the H-1 signals of GalNAc and GlcNAc is based on the appearance in the HOHAHA spectrum of the unique spin-coupling systems for GalNAc (H-1–H-4) and for GlcNAc (H-1–H-6/6'), respectively. Starting at H-1, all individual proton signals of GlcNAc could be assigned via the  $^1\text{H}$ – $^1\text{H}$  cross-peaks in the COSY spectrum. Furthermore, the GalNAc H-1,2,3,4 and H-5,6,6' spin systems were traced, and the two sets were correlated via an intraridical r.O.e. cross-peak between GalNAc H-1 and GalNAc H-5 in the 2D ROESY spectrum. For the full assignment of the proton signals of the Fuc residue in **GN(F)Gn**, the typical set of H-1, H-5 and  $\text{CH}_3$  signals formed the starting point [16]. The cross-peaks in the ROESY spectrum which correlate Fuc H-1 ( $^3J_{\text{H-1,H-2}}$ , 4 Hz) with GlcNAc H-3 (strong) and Fuc H-1 with GlcNAc H-4 (very weak), demonstrate that the Fuc residue is  $\alpha(1-3)$ -linked exclusively to the GlcNAc residue. The  $^1\text{H}$ -NMR data of **G(F)Gn** (Table I) are in good agreement with those reported for  $\text{Gal}\beta(1-4)[\text{Fuc}\alpha(1-3)]\text{GlcNAc}\beta(1-3)\text{Gal}\beta(1-4)\text{Glc}$  [14,18] and  $\text{Gal}\beta(1-4)[\text{Fuc}\alpha(1-3)]\text{GlcNAc}$  [19].







In the 2D ROESY spectrum of **GN(F)Gn**, a weak r.O.e. cross-peak between Fuc H-5 and GalNAc H-2 was observed. A similar r.O.e. contact has been found

for  $\text{Gal}\beta(1-4)[\text{Fuc}\alpha(1-3)]\text{GlcNAc}\beta(1-3)\text{Gal}\beta(1-4)\text{Glc}$ , i.e.  $\text{Fuc H-5} \leftrightarrow \text{Gal H-2}$ , originating from a rigid conformation of the  $\text{Le}^x$  trisaccharide element [14,20]. The presence of similar r.O.e. interactions in the  $\text{Le}^x$  and in the GalNAc variant of the  $\text{Le}^x$  element initiated a comparative conformation study of **G(F)Gn** and **GN(F)Gn**, which was focused on the influence of the replacement of OH by NAc at C-2'. The applied CHEAT force field has the advantage that no explicit solvent molecules have to be included in the calculation, because the average effect of inter- and intramolecular hydrogen bonding is covered by the potential energy function of the extended atom type for the hydroxyl groups. Two molecular dynamics (MD) simulations were performed for **G(F)Gn**, starting with the interglycosidic torsion angles of the minimum energy conformations **A** and **B** (Table II) of reference  $\text{Gal}\beta(1-4)[\text{Fuc}\alpha(1-3)]\text{GlcNAc}\beta\text{-OMe}$ , respectively, as presented in [14]. As can be deduced from the time-averaged interglycosidic torsion angles,  $\Phi_{\text{G}}/\Psi_{\text{G}}$  and  $\Phi_{\text{F}}[\text{G(F)Gn}]/\Psi_{\text{F}}[\text{G(F)Gn}]$  describing the  $\text{Gal}\beta(1-4)\text{GlcNAc}$  and the  $\text{Fuc}\alpha(1-3)\text{GlcNAc}$  linkages in **G(F)Gn**, respectively, the two MD runs for **G(F)Gn** produced essentially the same results (Table II). The time-averaged torsion angles match those of reference **MD1** and **MD2** [14], resulting from the MD simulations of minimum energy conformations **A** and **B**, respectively.

One MD simulation was performed for **GN(F)Gn** (Fig. 3) using the interglycosidic torsion angles of the lowest energy conformation **A** [14] as start parameters. Projections of the time-averaged conformations are depicted in Fig. 4. The time-averaged interglycosidic torsion angles,  $\Phi_{\text{GN}}/\Psi_{\text{GN}}$  and  $\Phi_{\text{F}}[\text{GN(F)Gn}]/\Psi_{\text{F}}[\text{GN(F)Gn}]$

Table 1

<sup>1</sup>H-NMR chemical shifts of **GNGn**, **G(F)Gn** and **GN(F)Gn**. Chemical shifts are given at 285 K and at 300 K, as indicated, in ppm downfield from internal acetone in <sup>2</sup>H<sub>2</sub>O ( $\delta$  2.225) [16]. Compounds are represented by short-hand symbolic notation: (□), L-Fuc; (●), D-GlcNAc; (■), D-Gal; (◇), D-GalNAc; Et, ethyl; Me, methyl. n.d., not determined.

Residue	Proton	Chemical shifts (ppm) in					
							
Temperature (K)		285	300	285	285	300	300
GlcNAc	H-1	4.552	4.561	4.433	4.422	4.438	4.433
	H-2	n.d.	3.87	3.733	3.915	3.712	3.905
	H-3	n.d.	3.86	3.714	3.822	3.682	3.832
	H-4	3.929	3.920	3.628	3.882	3.617	3.876
	H-5	3.585	3.584	3.521	3.524	3.520	3.523
	H-6	3.996	3.996	3.865	3.939	3.861	3.933
	H-6'	3.855	3.852	3.668	3.747	3.664	3.733
	NAc	2.028	2.028	2.026	2.018	2.027	2.019
OMe/OEt	CH <sub>3</sub>	1.157	1.157	3.497	3.489	3.498	3.489
	CH <sub>3</sub> /CH <sub>2</sub> '	n.d.	3.90/3.67	—	—	—	—
Fuc	H-1	5.107	5.104	—	5.107	—	5.102
	H-2	3.681	3.688	—	3.683	—	3.691
	H-3	3.907	3.902	—	3.939	—	3.931
	H-4	3.792	3.790	—	3.832	—	3.830
	H-5	4.856	4.830	—	4.871	—	4.839
	CH <sub>3</sub>	1.173	1.174	—	1.264	—	1.260
Gal/GalNAc	H-1	4.454	4.451	4.512	4.451	4.517	4.453
	H-2	3.496	3.494	3.928	3.985	3.928	3.970
	H-3	3.654	3.651	3.745	3.708	3.747	3.712
	H-4	3.890	3.899	3.935	3.902	3.940	3.909
	H-5	3.595	3.595	3.719	3.573	3.720	3.573
	H-6	3.740	3.742	3.799	3.768	3.797	3.769
	H-6'	3.731	3.724	3.757	3.718	3.765	3.713
	NAc	—	—	2.069	2.044	2.069	2.045

describing the GalNAc $\beta$ (1–4)GlcNAc and the Fuc $\alpha$ (1–3)GlcNAc linkages in **GN(F)Gn**, respectively, correspond with those of **G(F)Gn** (Table II). Like the Fuc and Gal residues in **G(F)Gn**, the Fuc and GalNAc residues in **GN(F)Gn** form a stacking complex, wherein the averaged distance between Gal/GalNAc H-2 and Fuc H-5 is 2.6 Å (Fig. 4), which is a realistic value for nuclear Overhauser effects. It should be noted that the trajectories of  $\Phi_F$  of reference Gal $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe shows a rapid change between two different dihedrals [14], whereas the trajectory of  $\Phi_F$  of **G(F)Gn** and of **GN(F)Gn** (Fig. 3) show basically one dihedral. Possibly, this difference in flexibility stems from the use of united atoms for the hydroxyl groups in the CHEAT forcefield.

#### 4. CONCLUDING REMARKS

Functionally purified preparations of human milk  $\alpha$ 3/4-fucosyltransferase have been used in the enzyme

assisted synthesis of  $\alpha$ (1 3)-fucosylated oligosaccharides, including Le<sup>x</sup> [7–9,12]. Here it is demonstrated that the enzyme can also be used to produce the GalNAc-containing variant of Le<sup>x</sup> in high yield. This finding implies that for a Gal $\beta$ (1–4)GlcNAc $\beta$ 1-R specific fucosyltransferase the OH group at C-2' can be replaced by a NAc group without a gross effect on the enzyme activity. Interestingly, it has been found previously that the Gal $\beta$ (1–4)GlcNAc $\beta$ 1-R  $\alpha$ (2–6)-sialyltransferase whether isolated from rat liver [10,21] or bovine colostrum [22] also can act on GalNAc $\beta$ (1–4)GlcNAc $\beta$ 1-R with high efficiency. In view of these results it will be of interest to investigate whether other Gal $\beta$ (1–4)GlcNAc $\beta$ 1-R specific glycosyltransferases such as  $\alpha$ (2 3)-sialyltransferase [23],  $\alpha$ 3-galactosyltransferase [24] and  $\beta$ 3-N-acetylglucosaminyltransferase [25] are similarly capable of acting on GalNAc $\beta$ (1–4)GlcNAc $\beta$ 1-R.

The average dihedrals and the corresponding fluctuations in the trajectories, and therefore the time-averaged




Fig. 3. The 1-ns trajectories of the interglycosidic torsion angles in GN(F)Gn: A,  $\Phi_{\text{GN}}$ ; B,  $\Psi_{\text{GN}}$ ; C,  $\Phi_{\text{F}}$ ; D,  $\Psi_{\text{F}}$ .

conformations of **G(F)Gn** and **GN(F)Gn** obtained from the MD simulations, show great similarity. Consequently, it can be concluded that the substitution of a hydroxyl function by a *N*-acetyl group, converting Gal into GalNAc, does not have a profound influence on the conformation of the trisaccharides. So far, the GalNAc variant of  $\text{Le}^x$ , carried on oligosaccharide alditols, released from sea squirt H-antigen [1], has been shown to induce allergic skin reactions in humans [26]. However, no role in interaction processes, as found for  $\text{Le}^x$  [27] and carbohydrate ligands having the  $\text{Le}^x$  epitope as structural element (sialyl- $\text{Le}^x$ , VIM-2 structure, sulfo-

$\text{Le}^x$ ) [28–30], has been reported. In this context, it should be mentioned that comparison of the time-averaged conformations of **G(F)Gn** and **GN(F)Gn** shows that Gal OH-2 and GalNAc NAc are oriented to the outside of the models. Since these functional groups seem to be explicitly present on the surface of the oligosaccharides, the replacement of Gal OH-2 by a NAc group in the  $\text{Le}^x$  sequence may affect the binding with carbohydrate-recognizing macromolecules. Whether (and if so to what extent) such a replacement has indeed a modulating effect on interactions events, mediated by  $\text{Le}^x$ -containing ligands, remains to be established.

Table II

Interglycosidic dihedral angles of the time-averaged conformations of **G(F)Gn** and **GN(F)Gn** given in degrees, together with those of reference Gal $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe

Compound	$\Phi_{\text{G}}/\Phi_{\text{GN}}$	$\Psi_{\text{G}}/\Psi_{\text{GN}}$	$\Phi_{\text{F}}$	$\Psi_{\text{F}}$
<b>G(F)Gn</b> (run 1)	–65 ( $\pm$ 9)	131 ( $\pm$ 8)	–61 ( $\pm$ 11)	–86 ( $\pm$ 9)
<b>G(F)Gn</b> (run 2)	–65 ( $\pm$ 9)	131 ( $\pm$ 7)	–61 ( $\pm$ 11)	–86 ( $\pm$ 10)
<b>GN(F)Gn</b>	–62 ( $\pm$ 10)	129 ( $\pm$ 8)	–56 ( $\pm$ 10)	–84 ( $\pm$ 9)
Reference:				
MD1	–61 ( $\pm$ 9)	128 ( $\pm$ 7)	–59 ( $\pm$ 20)	–88 ( $\pm$ 10)
MD2	–64 ( $\pm$ 10)	128 ( $\pm$ 8)	–64 ( $\pm$ 21)	–88 ( $\pm$ 11)
conformer A	–57	122	–45	–96
conformer B	–65	132	–83	–97

Conformations of **G(F)Gn** and **GN(F)Gn** were calculated from 1 ns molecular dynamics simulations using the force field CHEAT. The data of reference Gal $\beta$ (1–4)[Fuc $\alpha$ (1–3)]GlcNAc $\beta$ -OMe were collected from conformational energy calculations (conformer A and B) and from 300 ps molecular dynamics simulations (MD1 and MD2) using the force field CHARMM [14]. Interglycosidic torsion angles are defined as follows:  $\Phi_{\text{G}}/\Phi_{\text{GN}}$  = Gal/GalNAc O-5–Gal/GalNAc C-1–GlcNAc O-4–GlcNAc C-4;  $\Psi_{\text{G}}/\Psi_{\text{GN}}$  = Gal/GalNAc C-1–GlcNAc O-4–GlcNAc C-4–GlcNAc C-3;  $\Phi_{\text{F}}$  = Fuc O-5–Fuc C-1–GlcNAc O-3–GlcNAc C-3;  $\Psi_{\text{F}}$  = Fuc C-1–GlcNAc O-3–GlcNAc C-3–GlcNAc C-2. The values given in brackets are the root-mean-square fluctuations in the angles observed during the simulations.




Fig. 4. Diagram of the time-averaged conformations of (A) **G(F)Gn**, (B) **GN(F)Gn** and (C) superimposition of both models (cf. Table II). The ring-skeletons of the GlcNAc residues are presented from the same view-point.

**Acknowledgements:** This investigation was supported by the Netherlands Program for Innovation Oriented Carbohydrate Research (IOP-k), and by the Netherlands Foundation for Chemical Research (SON) with financial aid from the Netherlands Organization for Scientific Research (NWO).

## REFERENCES

- [1] Ohta, M., Matsuura, F., Kobayashi, Y., Shigeta, S., Ono, K. and Oka, S. (1991) *Arch. Biochem. Biophys.* **290**, 474–483.
- [2] Bergwerff, A.A., Thomas-Oates, J.E., Van Oostrum, J., Kamerling, J.P. and Vliegthart, J.F.G. (1992) *FEBS Lett.* **314**, 389–394.
- [3] Srivatsan, J., Smith, D.F. and Cummings, R.D. (1992) *Glycobiology* **2**, 445–452.
- [4] Kubelka, V., Altmann, F., Staudacher, E., Tretter, V., März, L., Hård, K., Kamerling, J.P. and Vliegthart, J.F.G. (1993) *Eur. J. Biochem.* **213**, 1193–1204.
- [5] Siciliano, R.A., Morris, H.R., McDowell, R.A., Azadi, P., Rogers, M.E., Bennett, H.P.J. and Dell, A. (1993) *Glycobiology* **3**, 225–239.
- [6] De Vries, T. and Van den Eijnden, D.H. (1992) *Histochem. J.* **24**, 761–770.
- [7] Beyer, T.A., Rearick, J.I., Paulson, J.C., Prieels, J.-P., Sadler, J.E. and Hill, R.L. (1979) *J. Biol. Chem.* **254**, 12531–12541.
- [8] Oehrlin, R., Hindsgaul, O. and Palcic, M.M. (1993) *Carbohydr. Res.* **244**, 149–159.
- [9] Joiasse, D.H., Schiphorst, W.E.C.M., Koeleman, C.A.M. and Van den Eijnden, D.H. (1993) *Biochem. Biophys. Res. Commun.* **194**, 358–367.
- [10] Hokke, C.H., Van der Ven, J.G.M., Kamerling, J.P. and Vliegthart, J.F.G. (1993) *Glycoconjugate J.* **10**, 82–90.
- [11] Eppenberger-Castori, S., Lötscher, H.R. and Finne, J. (1989) *Glycoconjugate J.* **6**, 101–114.
- [12] De Vries, T., Norberg, T., Lönn, H. and Van den Eijnden, D.H. (1993) *Eur. J. Biochem.*, in press.
- [13] Grootenhuys, P.D.J. and Haasnoot, C.A.G. (1993) *Mol. Sim.*, **10**, 75–95.
- [14] Miller, K.E., Mukhopadhyay, C., Cagas, P. and Bush, C.A. (1992) *Biochemistry* **31**, 6703–6709.
- [15] IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) (1983) *Eur. J. Biochem.* **131**, 81–88.
- [16] Vliegthart, J.F.G., Dorland, L. and Van Halbeek, H. (1983) *Adv. Carbohydr. Chem. Biochem.* **41**, 209–374.
- [17] Hård, K., Van Zadelhoff, G., Moonen, P., Kamerling, J.P. and Vliegthart, J.F.G. (1992) *Eur. J. Biochem.* **209**, 895–915.
- [18] Homans, S.W. (1992) *Glycobiology* **2**, 153–159.
- [19] Hounsell, E.F., Jones, N.J., Gooi, H.C. and Feizi, T. (1988) *Carbohydr. Res.* **178**, 67–78.
- [20] Wormald, M.R., Edge, C.J. and Dwek, R.A. (1991) *Biochem. Biophys. Res. Commun.* **180**, 1214–1221.
- [21] Hokke, C.H., Van der Ven, J.G.M., Kamerling, J.P. and Vliegthart, J.F.G. (1991) *Glycoconjugate J.* **8**, 259.
- [22] Nemansky, M. and Van den Eijnden, D.H. (1992) *Biochem. J.* **287**, 311–316.
- [23] Nemansky, M. and Van den Eijnden, D.H. (1993) *Glycoconjugate J.* **10**, 99–108.
- [24] Joiasse, D.H., Shaper, N.L., Salyer, L.S., Van den Eijnden, D.H., Van der Spoel, A.C. and Shaper, J.H. (1990) *Eur. J. Biochem.* **191**, 75–83.
- [25] Van den Eijnden, D.H., Koenderman, A.H.L. and Schiphorst, W.E.C.M. (1988) *J. Biol. Chem.* **263**, 12461–12471.
- [26] Ohta, M., Shigeta, S., Ono, K., Takao, T., Shimonishi, Y. and Oka, S. (1989) *Arch. Biochem. Biophys.* **275**, 151–165.
- [27] Eggens, J., Fenderson, B., Toyokuni, T., Dean, B., Stroud, M. and Hakomori, S.-I. (1989) *J. Biol. Chem.* **264**, 9476–9484.
- [28] Tyrrell, D., James, P., Rao, N., Foxall, C., Abbas, S., Dasgupta, F., Nashed, M., Hasegawa, A., Kiso, M., Asa, D. and Kidd, J. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 10372–10376.
- [29] Asa, D., Gant, T., Oda, Y. and Brandley, B.K. (1992) *Glycobiology* **2**, 395–399.
- [30] Green, P.J., Tamatani, T., Watanabe, T., Miyasaka, M., Hasegawa, A., Kiso, M., Yuen, C.T., Stoll, M.S. and Feizi, T. (1992) *Biochem. Biophys. Res. Commun.* **188**, 244–251.